



Current Aspects on the Therapeutics of Aging, Cellular Senescence and Neurodegenerative Diseases

Guest Editor:

Dr. Ashok Iyaswamy

School of Chinese Medicine,
Hong Kong Baptist University,
Hong Kong

Deadline for manuscript
submissions:

closed (30 September 2024)

Message from the Guest Editor

Aging is an inevitable process causing deteriorations in brain function. An accumulation of damaged proteins, inflammation and cell death have all been linked to cellular aging, which has been linked with the development of neurodegenerative disorders. At present, exploring cellular senescence as a potential therapeutic target for addressing neurodegenerative diseases has increasingly received the attention of researchers. Despite a plethora of laboratory as well as clinical research, there is a dearth of effective medicine. Therefore, it poses great challenges for researchers in the scientific community and medical experts to tackle the unresolved problems of disease pathogenesis and therapeutics for aging, cellular senescence and neurodegenerative diseases. Among the most promising strategies for drug discovery is employing traditional herbal medicine for the modulation of memory improvement and toxic protein degradation in aging, cellular senescence and neurodegenerative diseases therapy.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)